Phase I/II Study of the Safety, Tolerability, and Efficacy of Stereotactic Body Radiation Therapy (SBRT) Combined With Concurrent and Adjuvant Avelumab for Definitive Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Latest Information Update: 12 Aug 2024
At a glance
- Drugs Avelumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 29 Apr 2021 Status changed from active, no longer recruiting to discontinued.
- 04 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 13 Nov 2018 Planned End Date changed from 1 Mar 2021 to 1 Oct 2021.